康希诺生物(06185.HK) 公布,已获得印尼食品药品监督管理局颁发的I期临床试验批准,可以启动公司开发的吸入用肺结核疫苗(5型腺病毒载体)的相关临床试验。
I期临床试验目的是在18至49岁的成年人中探究接种一剂吸入用结核病加强疫苗的安全性和免疫原性。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-15 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.